CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

TG Therapeutics, Inc.

TGTX
$8.64BMid Cap

Next catalyst

Phase 3January 2027

Ublituximab

Non-Hodgkins Lymphoma

Get an email about TGTX's next catalysts

Track TG Therapeutics (TGTX) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.

Plus 1 more upcoming event in our data (Phase 2 readout).See the timeline

Catalyst Timeline

2 upcoming, 3 past

Phase 3Next

Ublituximab Phase 3 Est. Readout (ENHANCE)

January 2027~Ublituximab800

Primary completion for Ublituximab trial (NCT07211633) in Relapsing Multiple Sclerosis

Source
Phase 2

Ublituximab Phase 2 Est. Readout

Q3 2027~QUblituximab350

Estimated primary completion for Ublituximab trial (NCT07503873) in Multiple Sclerosis. Topline data typically follows completion by weeks to months.

Source

How TGTX's past catalysts played out

Market Overview

Stock performance and key metrics

NASDAQPharmaceutical PreparationsπŸ‡ΊπŸ‡ΈNorth AmericaNEW YORK374 employees
Drug Pipeline

Frequently asked questions

What is in TG Therapeutics, Inc.'s drug pipeline?β†’

CatalystAlert tracks 3 drug candidates in TG Therapeutics, Inc.'s (TGTX) pipeline across Phase 3, Phase 2. Its lead program is Ublituximab (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.

When is TG Therapeutics, Inc.'s next FDA catalyst?β†’

TG Therapeutics, Inc.'s (TGTX) next tracked catalyst is a Phase 3 readout expected January 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.

How do I track TGTX biotech catalysts?β†’

Add TGTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow TG Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page β€” sourced from ClinicalTrials.gov, FDA and SEC filings.

Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply